T. Rowe Price Reveals 10.5% Ownership Stake in Dianthus Therapeutics
T. Rowe Price Investment Management, Inc. has disclosed a 10.5% beneficial ownership stake in Dianthus Therapeutics Inc., holding 5,885,888 shares of common stock as of September 30, 2026. This information was revealed in an Amendment No. 2 to its Schedule 13G filing with the SEC on November 16, 2026. The firm has sole voting and dispositive power over most of these shares, affirming the acquisition was in the ordinary course of business and not for influencing control of the issuer.
T. Rowe Price reports 5.89M shares in Dianthus Therapeutics (DNTH) in passive stake amendment.
T. Rowe Price Investment Management, Inc. has filed an amended passive investment disclosure (SCHEDULE 13G/A) for Dianthus Therapeutics, Inc. (DNTH). The report indicates beneficial ownership of 5,885,888 shares, representing 10.5% of the common stock, as of September 30, 2026. T. Rowe Price explicitly denies that this report is an admission of beneficial ownership.
Dianthus Therapeutics evp Savitz sells $11.2M in stock
Ryan Savitz, EVP, CFO, and CBO of Dianthus Therapeutics (NASDAQ:DNTH), sold approximately $11.2 million worth of common stock between November 9 and November 12, 2026, executing a Rule 10b5-1 trading plan. Concurrently, Savitz exercised stock options to acquire 120,042 shares for about $2.46 million, which were then immediately sold. Despite the sales, Dianthus has received positive analyst coverage and price target increases from Raymond James, Roth/MKM, and JPMorgan due to its progress in neuromuscular treatments and promising drug candidate, claseprubart.
Form 4 Dianthus Therapeutics Inc: Ryan Savitz (EVP, CFO & CBO) For: 9 November By Investing.com
This article reports on a Form 4 filing for Dianthus Therapeutics Inc, specifically regarding Ryan Savitz, who holds the titles of EVP, CFO, and CBO. The filing pertains to activity on November 9th. The article notes the company's stock symbol DNTH and includes a positive stock performance figure.
Dianthus Therapeutics (NASDAQ:DNTH) EVP Sells $9,118,555.02 in Stock
Dianthus Therapeutics EVP Ryan Savitz sold 100,713 shares of the company's stock for approximately $9.12 million, significantly reducing his holdings. The company recently reported a quarterly loss of $0.81 per share, which was better than analyst expectations, and revenue of $1.21 million, exceeding estimates. Shares of DNTH traded up 3.6% following the news, and analysts maintain a "Buy" consensus rating with an average price target of $128.77.
Dianthus Therapeutics (NASDAQ:DNTH) EVP Sells $230,848.54 in Stock
Dianthus Therapeutics EVP Ryan Savitz sold 2,561 shares of DNTH stock for approximately $230,849, reducing his direct holdings by 8.04%. This sale follows several other significant transactions by Savitz in early November. Despite the insider selling, DNTH shares rose 3.6% to $92.48, and the company reported a narrower-than-expected quarterly loss and revenue that exceeded analyst estimates.
Insider Selling: Dianthus Therapeutics (NASDAQ:DNTH) EVP Sells $274,051.32 in Stock
Dianthus Therapeutics EVP Ryan Savitz sold 3,044 shares of the company's stock for $274,051.32 on November 11th, reducing his ownership by 9.42%. This sale is part of several recent transactions by Savitz, including larger sales totaling over $10 million in the days prior. Despite the insider selling, Dianthus Therapeutics shares traded up on Thursday, and the company recently beat quarterly earnings and revenue estimates, maintaining a consensus "Buy" rating from analysts with a target price of $128.77.
Dianthus Therapeutics (DNTH) CFO exercises options and sells shares under a preset plan.
Dianthus Therapeutics' EVP, CFO & CBO, Ryan Savitz, exercised options for 124,042 common shares and subsequently sold the same number of shares between November 9 and November 12, 2026. These transactions, involving various option exercise prices and weighted-average sale prices, were conducted under a Rule 10b5-1 trading plan adopted on August 7, 2026. Following these transactions, Savitz holds 176,884 stock options and no common stock directly.
Form 4 Dianthus Therapeutics Inc: Ryan Savitz (EVP, CFO & CBO) For: 9 November
This article reports on a Form 4 filing for Dianthus Therapeutics Inc, detailing transactions by Ryan Savitz, the EVP, CFO & CBO, related to November 9. Form 4 filings disclose changes in beneficial ownership of a company's securities by insiders. The article includes the stock symbol DNTH and mentions its current performance.
Dianthus Therapeutics (DNTH) Stock May Look Stretched As Pipeline Progress Draws Focus
Dianthus Therapeutics (DNTH) has seen a significant 3-year gain, prompting questions about whether its share price is justified by its balance sheet and pipeline progress. The stock trades at a P/B ratio of 4.1x, which is considerably higher than the biotech sector average of 1.8x, suggesting it may be overvalued based on book value alone. However, an analyst consensus narrative suggests the company is 36% undervalued, believing the market is not fully pricing in the potential revenue from its pipeline assets.
Form 144 Dianthus Therapeutics For: 10 November By Investing.com
This article from Investing.com announces a Form 144 filing for Dianthus Therapeutics on November 10th. Form 144 is a notice of the intent to sell restricted securities, indicating potential insider activity or significant share transactions. The brief update highlights the company's stock symbol DNTH and its recent price performance.
Dianthus Therapeutics Officer Ryan Savitz Announces Intent to Sell 124,042 Shares via Stock Option Exercise
Ryan Savitz, an officer at Dianthus Therapeutics, Inc., plans to sell 124,042 common shares, valued at approximately $10.67 million, which he acquired through stock option exercises. This intention was disclosed in a Form 144 filing on November 9, 2026. The sale will be executed on the NASDAQ exchange and is part of a Rule 10b5-1 trading plan adopted on August 7, 2026.
An officer proposes selling 124,042 shares of Dianthus Therapeutics (DNTH).
Dianthus Therapeutics officer Ryan Savitz has filed a notice for the proposed sale of 124,042 common shares, valued at $10.67 million. These shares are slated to be acquired through stock-option exercises over the next three months, with an approximate sale date of November 9, 2026. The plan for this sale, relying on Rule 10b5-1, was adopted on August 7, 2026.
18,801 Dianthus Therapeutics, Inc. $DNTH Shares Acquired by Alps Advisors Inc.
Alps Advisors Inc. increased its stake in Dianthus Therapeutics (NASDAQ:DNTH) by 34% in the third quarter, acquiring an additional 18,801 shares to bring its total holdings to 74,082 shares valued at approximately $6.5 million. Other institutional investors have also adjusted their positions in the company, with institutional investors collectively owning 47.53% of the stock. Despite recent insider selling, analysts maintain a consensus "Buy" rating for Dianthus Therapeutics, with an average price target of $128.77, and the company recently reported a narrower-than-expected quarterly loss and better-than-anticipated revenue.
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dianthus Therapeutics, Inc. announced that it granted equity awards to three newly-hired, non-executive employees on November 2, 2026. These inducement grants, consisting of non-qualified stock options for 26,000 shares, were approved by the Company's independent Compensation Committee as material inducements for employment, in accordance with Nasdaq Listing Rule 5635(c)(4). The options have a 10-year term, an exercise price of $82.25 per share, and vest over four years.
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dianthus Therapeutics, Inc. announced that it granted equity awards to three newly-hired, non-executive employees on November 2, 2026. These inducement grants, approved by the Company's Compensation Committee, consist of non-qualified stock options for an aggregate of 26,000 shares of common stock. The grants were made as material inducements for employment, in compliance with Nasdaq Listing Rule 5635(c)(4).
Dianthus Therapeutics to Participate in Five Investor Conferences During November
Dianthus Therapeutics, a clinical-stage biotechnology company, announced its participation in five investor conferences in November 2026. CEO Marino Garcia and EVP, CFO & CBO Ryan Savitz will engage in fireside chats and one-on-one meetings with investors at events hosted by Guggenheim, Stifel, Truist Securities, UBS, and Jefferies. The company specializes in developing therapies for severe autoimmune diseases.
Dianthus Therapeutics, Inc. (DNTH) Seasonal returns chart
This article from Yahoo Finance presents the historical seasonality of Dianthus Therapeutics, Inc. (DNTH) stock. It displays the average monthly price return from 2018 to 2026, offering insights into potential seasonal trends for the company's stock performance. The current stock price and daily change are also provided.
Vanguard reports a passive stake above 5% in Dianthus Therapeutics (DNTH).
Vanguard Capital Management has reported a 5.08% passive stake in Dianthus Therapeutics (DNTH) through a Schedule 13G SEC filing. This stake includes 2,846,786 common shares, with Vanguard Capital Management holding sole voting power over 418,713 shares and sole dispositive power over all 2,846,786 shares. The filing indicates that the shares were acquired in the ordinary course of business and not for the purpose of influencing company control.
Dianthus Therapeutics (DNTH) Expected to Release Earnings on Thursday
Dianthus Therapeutics (NASDAQ: DNTH) is scheduled to release its Q3 2026 earnings after market close on Thursday, November 5th. Analysts anticipate a loss of $0.9445 per share and revenue of $0.46 million. The company previously missed earnings estimates, and despite recent insider selling and stock volatility, analysts maintain a "Buy" rating with an average price target of $128.54.
Roth/MKM initiates Dianthus Therapeutics stock at buy on drug profile
Roth/MKM has initiated coverage on Dianthus Therapeutics (NASDAQ:DNTH) with a "buy" rating and a price target of $113.00, citing the strong profile of its drug candidate, claseprubart. The firm highlights claseprubart's rapid clinical activity and infrequent self-injection, anticipating its potential as a best-in-class treatment across three neuromuscular indications. Investors are advised to build positions ahead of upcoming clinical data readouts in late 2026, with pivotal results expected in 2028.
Dianthus Therapeutics, Inc. Estimates – NASDAQ:DNTH
This article provides an overview of Dianthus Therapeutics, Inc. (NASDAQ: DNTH) financials and estimates available on TradingView. It directs users to explore reported financial data and analyst estimates across various financial statements and valuation metrics. The content emphasizes comparing actual results with estimates and visualizing trends over time, with a disclaimer that it is not investment advice.
451,597 Dianthus Therapeutics, Inc. $DNTH Shares Purchased by Assenagon Asset Management S.A.
Assenagon Asset Management S.A. significantly increased its stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 160.9% in the third quarter, purchasing 451,597 additional shares and now owning 1.34% of the company. Other institutional investors also bought into the company, while insiders, including CAO Edward Carr and SVP Adam M. Veness, sold a substantial number of shares. Analysts have a "Moderate Buy" consensus rating for DNTH with an average price target of $129.83.
Dianthus Therapeutics, Inc. (DNTH) options chain
This article provides an options chain for Dianthus Therapeutics, Inc. (DNTH), showing real-time stock information and delayed options data. As of the report, there are no calls or puts listed for the company. The stock closed at $72.09, down 3.27%, with no change in after-hours trading.
HC Wainwright & Co. reiterates Buy rating on Dianthus Therapeutics, $158 price target
HC Wainwright & Co. has reiterated its Buy rating on Dianthus Therapeutics (DNTH) with a price target of $158.00, suggesting a significant upside of 111.3% from its previous close. This valuation is based on a risk-adjusted net present value (rNPV) analysis of its lead product, claseprubart, and the company's strong financial position with approximately $887 million in net cash. The firm expresses confidence in Dianthus Therapeutics' potential for effective treatments in severe autoimmune diseases.
Dianthus Therapeutics (NASDAQ:DNTH) Earns "Buy" Rating from HC Wainwright
HC Wainwright has reaffirmed a "Buy" rating for Dianthus Therapeutics (NASDAQ:DNTH) with a $158 price target, indicating a potential upside of 112% from its previous closing price. Despite this positive outlook and a consensus "Moderate Buy" rating from analysts, the company recently reported a quarterly loss that missed estimates, and significant insider selling has occurred. Dianthus Therapeutics is a clinical-stage biotechnology company focusing on developing targeted antibody therapies for autoimmune diseases.
Dianthus Therapeutics, Inc. (DNTH) Options Chain - Yahoo Finance
This page provides the options chain for Dianthus Therapeutics, Inc. (DNTH), listed on NasdaqCM. It displays call and put options with an expiration date of March 19, 2027, detailing strike prices, last trade dates, last prices, bids, asks, and implied volatility. The article also includes current stock price information and links to related financial data for DNTH.
Dianthus Therapeutics, Inc. (DNTH) Options Chain
This article provides the options chain for Dianthus Therapeutics, Inc. (DNTH). As of the provided data, there are no calls or puts listed as "In The Money" for the contract with a last trade date of February 19, 2027. The stock closed at $74.76, down 3.63%.
Dianthus Therapeutics Recognized Among Fortune’s 2026 Best Workplaces In BioPharma
Dianthus Therapeutics, Inc. has been selected for Fortune's 2026 Best Workplaces in BioPharma List, marking its first appearance and ranking among the top small- and medium-sized companies. The company was recognized for its high-trust and engaging workplace culture, which its CEO, Marino Garcia, attributes to a shared commitment to values and high performance. This recognition is based on confidential employee surveys analyzed by Great Place To Work.
Dianthus Therapeutics Named to Fortune’s 2026 Best Workplaces in BioPharma List Amid Company Expansion
Dianthus Therapeutics (NASDAQ:DNTH) has been recognized on Fortune's 2026 Best Workplaces in BioPharma list for the first time, highlighting its strong employee culture and fully remote operating model. This acknowledgement comes as the clinical-stage biotechnology company actively expands its workforce and develops therapies for severe autoimmune diseases. While not a direct financial catalyst, the recognition is seen as beneficial for attracting and retaining talent, which is crucial for advancing its research programs and clinical operations.
More than 1.3 million employee surveys shaped Fortune's workplace list. Dianthus made it for the first time.
Dianthus Therapeutics (Nasdaq: DNTH) has been named to Fortune’s 2026 Best Workplaces in BioPharma list, marking its inaugural appearance. The company ranked among the top 30 small- and medium-sized biotechnology and pharmaceutical firms in the U.S. This recognition is based on nearly 36,000 employee responses from certified biotechnology and pharmaceutical companies, highlighting Dianthus's high-trust and engaging workplace culture.
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Stock Has Consensus Target Price of $129.83
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) has received a "Moderate Buy" consensus recommendation from analysts, with an average 12-month price target of $129.83, significantly above its current share price of $84.88. Despite strong institutional ownership at 47.53%, company insiders have heavily sold shares worth approximately $26.1 million over the past three months, reducing their ownership to 3.02%. The company recently reported a quarterly loss of $0.90 per share, missing estimates, but exceeded revenue expectations at $0.76 million.
LifeSci Capital Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Maintains Target Price $125
LifeSci Capital has reiterated its Buy rating on Dianthus Therapeutics (DNTH.US) and maintained its target price of $125. The firm's continued endorsement suggests confidence in the company's prospects.
Dianthus Therapeutics Announces Claseprubart Oral and Poster Presentations at AANEM Annual Meeting
Dianthus Therapeutics announced upcoming oral and poster presentations for its investigational therapy, claseprubart, at the AANEM Annual Meeting. These presentations will highlight positive results from the Phase 2 MaGic trial and Phase 3 CAPTIVATE trial, showcasing claseprubart's potential as a new treatment for generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP). The company also provided updates on its clinical pipeline, including expected top-line data for other trials in late 2026 and 2028.
Dianthus Therapeutics Inc (DNTH-Q) Stock Price and News
This article provides stock information and news headlines for Dianthus Therapeutics Inc. (DNTH-Q), including recent analyst ratings, reports on its Phase 3 EMERGE trial for Claseprubart, and its status as a clinical-stage biotechnology company. The news highlights various analyst opinions on the stock and its recent advancements.
Dianthus Therapeutics, Inc. (DNTH) Stock Price, News, Quote & History
This article provides comprehensive financial data for Dianthus Therapeutics, Inc. (DNTH), including its stock price, historical data, and performance metrics against the S&P 500. It also details the company's overview, its clinical-stage biotechnology developments, and analyst insights, such as price targets and recommendations. Key financial highlights and earnings trends are presented to offer a complete picture of the company's market position.
Bank of America Corp DE Takes Position in Dianthus Therapeutics, Inc. $DNTH
Bank of America Corp DE has acquired a new position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH), purchasing 256,833 shares valued at approximately $25 million, representing a 0.47% stake in the company. Despite institutional ownership of 47.53% and a "Moderate Buy" consensus rating from analysts, DNTH shares recently fell by 5.0% after the company reported a quarterly loss that missed consensus estimates. Over the past 90 days, company insiders have sold a significant amount of shares totaling $29.3 million.
Engineers Gate Manager LP Reduces Holdings in Dianthus Therapeutics, Inc. $DNTH
Engineers Gate Manager LP significantly reduced its stake in Dianthus Therapeutics (NASDAQ:DNTH) by 47.1% in Q2 2026, selling 10,330 shares. Despite this reduction, institutional investors collectively own 47.53% of the company. Dianthus Therapeutics shares opened down 4.3% at $96.81, and the company reported a quarterly loss of $0.90 per share, missing analyst estimates, though revenue exceeded expectations.
Dianthus (NASDAQ: DNTH) officer set to sell 20,000 shares
An officer of Dianthus Therapeutics, Edward Carr, has filed a Rule 144 notice to sell up to 20,000 shares of common stock. These shares, valued at $2,049,800, result from an exercise of stock options for cash on September 17, 2026. The sale will be executed through Morgan Stanley Smith Barney LLC, with Dianthus Therapeutics having 55,934,378 shares outstanding as of the referenced date.
Dianthus Therapeutics R&D Head Randhawa Simrat Retains 4,000 Shares After Exercising and Selling Options
Randhawa Simrat, Executive Vice President and Head of Research and Development at Dianthus Therapeutics, exercised options for 23,124 shares on September 1, 2026. Following the exercise, Simrat sold all 23,124 shares, with sale prices ranging from $105.19 to $106.74 per share. After these transactions, Simrat retained 4,000 shares and holds 87,500 derivative securities.
Dianthus stock gains new Buy from Citi (DNTH:NASDAQ)
Citi has initiated a Buy rating on Dianthus Therapeutics (DNTH), citing a multibillion-dollar sales potential for its lead drug, claseprubart. Dianthus is a biotech company focused on developing treatments for autoimmune conditions. The analyst's positive outlook is based on the significant market opportunity for the complement inhibitor.
Officer at Dianthus (NASDAQ: DNTH) lines up 2026 stock sale after option exercise
An officer at Dianthus Therapeutics, Inc. (DNTH), Simrat Randhawa, has filed a Rule 144 notice to sell up to 23,124 shares of common stock on or after September 1, 2026. These shares, valued at an aggregate market value of $2,442,125.64, will be acquired through the exercise of stock options for cash. The sale will be executed via Morgan Stanley Smith Barney LLC on NASDAQ.
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dianthus Therapeutics, Inc. (Nasdaq: DNTH) announced equity awards granted on September 1, 2026, to four newly-hired, non-executive employees. These inducement grants, approved by the Company's independent Compensation Committee, consist of non-qualified stock options to purchase an aggregate of 52,000 shares of common stock at an exercise price of $106.62 per share, vesting over four years. This action is in accordance with Nasdaq Listing Rule 5635(c)(4).
Dianthus Therapeutics to Participate in Three Investor Conferences During September
Dianthus Therapeutics, a clinical-stage biotechnology company focused on autoimmune diseases, announced its participation in three investor conferences in September 2026. CEO Marino Garcia and other executives will host one-on-one meetings and participate in fireside chats at the Wells Fargo, Citi's Biopharma, and Cantor Global Healthcare Conferences to discuss the company's progress and vision. Webcasts for the Citi and Cantor events will be available on the company's website.
DNTH Shares Surge 89% Over the Past Six Months: What's Driving It?
Dianthus Therapeutics (DNTH) shares have surged 88.9% in the past six months, driven by investor confidence in its lead asset, claseprubart, and a strong financial position. The company is advancing claseprubart for multiple autoimmune diseases, with pivotal phase III trials underway or planned for gMG and CIDP. Additionally, Dianthus's second pipeline candidate, DNTH212, is progressing through phase I studies for several autoimmune disorders, supported by a robust cash reserve of $1.2 billion.
Bank of America Corp DE Trims Stake in Dianthus Therapeutics, Inc. $DNTH
Bank of America Corp DE significantly reduced its stake in Dianthus Therapeutics (NASDAQ:DNTH) by 59.4% in the first quarter, selling over 276,000 shares but still retaining a holding worth approximately $15.8 million. Despite this, institutional investors collectively own 47.53% of the stock, and analysts maintain a "Moderate Buy" rating with an average price target of $124.27. Recent insider selling has also occurred, with over $29 million worth of shares sold in the last three months, even as the company's stock approaches its 52-week high.
Dianthus Therapeutics director Simon Read sells $326,553 in stock
Dianthus Therapeutics director Simon Read sold 2,778 shares of company stock for $326,553 on August 19, 2026, after exercising stock options under a Rule 10b5-1 trading plan. The sale occurred near the stock's 52-week high, with the company showing a 401% return over the past year. Despite the insider sale, recent news indicates strong analyst confidence due to positive Q2 earnings, the development of DNTH312, and promising clinical trial data for claseprubart.
Dianthus Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Read Simon
This document is a statement of changes in beneficial ownership of securities for Director Read Simon of Dianthus Therapeutics, filed as a Form 4. It indicates transactions related to his holdings in the company.
Eagle Health Investments LP Takes Position in Dianthus Therapeutics, Inc. $DNTH
Eagle Health Investments LP has acquired 131,344 shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) valued at approximately $12.8 million, making it their 20th largest holding. Despite this institutional interest and a "Moderate Buy" consensus rating from analysts, insiders have recently sold a significant amount of stock, totaling nearly $29.6 million. Dianthus Therapeutics reported a quarterly loss but exceeded revenue expectations, and the company is developing complement therapeutics for autoimmune and inflammatory diseases.
Royal Bank of Canada Has $1.60 Million Stock Holdings in Dianthus Therapeutics, Inc. $DNTH
Royal Bank of Canada significantly increased its stake in Dianthus Therapeutics, Inc. by 847.5% in the first quarter, now holding 19,064 shares valued at $1.60 million. Despite the company missing EPS estimates, institutional investors collectively own 47.53% of the stock, and Wall Street analysts maintain a "Moderate Buy" rating with an average price target of $124.27. However, recent insider selling, including by the CEO and a director, totals approximately $29.6 million over the past 90 days.